Guidelines of care for the use of topical glucocorticosteroids

Journal of the American Academy of Dermatology

Volumn 35, Issue 4, 1996, Pages 615-619

  Drake, Lynn A ^a   Dinehart, Scott M ^a   Farmer, Evan R ^a   Goltz, Robert W ^a   Graham, Gloria F ^a   Hordinsky, Maria K ^a   Lewis, Charles W ^a   Pariser, David M ^a   Webster, Stephen B ^a   Whitaker, Duane C ^a   Butler, Barbara ^a   Lowery, Barbara J ^a   Raimer, Sharon A ^a   Krafchik, Bernice R ^a   Olsen, Elise ^a   Weston, William L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; GLUCOCORTICOID; HYDROCORTISONE;

ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; CATARACT; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; GROWTH RETARDATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN DISEASE; SKIN TOXICITY; TOPICAL DRUG ADMINISTRATION;

EID: 12644262385     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90690-8     Document Type: Article

References (32)

1. Barry BW, Woodford R. Comparative bioavailability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments. Br J Dermatol 1975;93:563-71.
2. Barry BW, Woodford R. Comparative bio-availability of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty creams and gels. Br J Dermatol 1974;91:323-38.
3. Bartorelli A, Rimondini A. Severe hypertension in childhood due to prolonged skin application of a mineralocorticoid ointment. Hypertension 1984;6:586-8.
4. Becker B. Cataracts and topical corticosteroids. Am J Ophthalmol 1964;58:872-3.
5. Becker B. The effect of topical corticosteroids in secondary glaucomas. Arch Ophthalmol 1964;72:769-71.
6. Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA 1980;244:813-4.
7. Brattsand R, Thalen A, Roempke K, et al. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem 1982;16:779-86.
8. Bucks DA, McMaster JR, Maibach HI, et al. Bioavailability of topically administered steroids: a mass balance technique. J Invest Dermatol 1988;91:29-33.
9. Cornell RC. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol 1992;31:38-40.
10. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-7.
11. Curtis JA, Cormode E, Laski B, et al. Endocrine complications of topical and intralesional corticosteroid therapy. Arch Dis Child 1982;57:204-7.
12. Goette DK, Odom RB. Adverse effects of corticosteroids. Cutis 1979;23:477-87.
13. Guin JD. Contact sensitivity to topical corticosteroids. J Am Acad Dermatol 1984;10:773-82.
14. Hepburn D, Yohn JJ, Weston WL. Topical steroid treatment in infants, children and adolescents. Adv Dermatol 1994;9:225-54.
15. Jackson DB, Thompson C, McCormack JR, et al. Bioequivalence (bioavailability) of generic topical corticosteroids. J Am Acad Dermatol 1989;20:791-6.
16. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183:269-74.
17. Katz HI, Prawer SE, Mooney JJ, et al. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol 1989;20:731-5.
18. Kligman AM. Adverse effects of topical corticosteroids. In: Christophers E, Schopf E, Kligman AM, et al, editors. Topical corticosteroid therapy: a novel approach to safer drugs. New York: Raven Press, 1988:181-7.
19. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979;18:23-31.
20. Lepoittevin JP, Drieghe J, Dooms-Goossens A. Studies in patients with corticosteroid contact allergy: understanding cross-reactivity among different steroids. Arch Dermatol 1995;131:31-7.
21. Marks R. Survey of methods for assessment of corticosteroid atrophogenicity. In: Christophers E, Schopf E, Kligman AM, et al, editors. Topical corticosteroid therapy: a novel approach to safer drugs. New York: Raven Press, 1988:105-10.
22. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608-10.
23. Queille C, Pommarede R, Saurat J. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1:246-53.
24. Schlagel CA, Sanborn EC. The weights of topical preparations required for total and partial body inunction. J Invest Dermatol 1964;42:253-6.
25. Shah VP, Peck CC, Skelly JP. 'Vasoconstriction'-skin blanching-assay for glucocorticoids: a critique. Arch Dermatol 1989;125:1558-61.
26. Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol 1986;25:324-6.
27. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987; 123:1312-4.
28. Stoughton RB. The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments. Int J Dermatol 1992;31:26-8.
29. Timmins P, Gray EA: Degradation of hydrocortisone in a zinc oxide lotion. J Clin Hosp Pharm 1983;8:79-85.
30. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-84.
31. Vermeer BJ, Heremans GFP. A case of growth retardation and Gushing's syndrome due to excessive application of betamethasone-17-valerate ointment. Dermatologica 1974; 149:299-304.
32. Yohn JJ, Weston WL. Topical glucocorticosteroids. Curr Probl Dermatol 1990;2:31-63.